Invivyd Inc. (IVVD) - Total Assets
Based on the latest financial reports, Invivyd Inc. (IVVD) holds total assets worth $241.74 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See IVVD net asset quality index to measure how much of total assets are equity-financed.
Invivyd Inc. - Total Assets Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s total assets have evolved over time, based on quarterly financial data. Check IVVD tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Invivyd Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Invivyd Inc.'s total assets of $241.74 Million consist of 89.4% current assets and 10.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 81.9% |
| Accounts Receivable | $13.92 Million | 5.0% |
| Inventory | $25.50 Million | 9.2% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2020–2025)
This chart illustrates how Invivyd Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see IVVD market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Invivyd Inc.'s current assets represent 89.4% of total assets in 2025, a decrease from 100.0% in 2020.
- Cash Position: Cash and equivalents constituted 81.9% of total assets in 2025, down from 98.0% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2020.
- Asset Diversification: The largest asset category is inventory at 9.2% of total assets.
Invivyd Inc. Competitors by Total Assets
Key competitors of Invivyd Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $8.59 Billion |
|
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
|
USA | $4.40K |
|
Krystal Biotech Inc
NASDAQ:KRYS
|
USA | $1.40 Billion |
|
Verona Pharma PLC ADR
NASDAQ:VRNA
|
USA | $572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
BB Biotech AG
SW:BION
|
Switzerland | CHF2.64 Billion |
Invivyd Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.47 | 1.53 | 10.45 |
| Quick Ratio | 5.67 | 1.52 | 10.45 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $173.26 Million | $26.23 Million | $358.16 Million |
Invivyd Inc. - Advanced Valuation Insights
This section examines the relationship between Invivyd Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.31 |
| Latest Market Cap to Assets Ratio | 0.86 |
| Asset Growth Rate (YoY) | 113.8% |
| Total Assets | $276.88 Million |
| Market Capitalization | $239.37 Million USD |
Valuation Analysis
Near Book Valuation: The market values Invivyd Inc.'s assets close to their book value (0.86x), suggesting investors view the company's assets at approximately fair value.
Rapid Asset Growth: Invivyd Inc.'s assets grew by 113.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Invivyd Inc. (2020–2025)
The table below shows the annual total assets of Invivyd Inc. from 2020 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $276.88 Million | +113.78% |
| 2024-12-31 | $129.51 Million | -43.49% |
| 2023-12-31 | $229.18 Million | -40.19% |
| 2022-12-31 | $383.17 Million | -38.21% |
| 2021-12-31 | $620.09 Million | +428.27% |
| 2020-12-31 | $117.38 Million | -- |
About Invivyd Inc.
Invivyd, Inc., together with its subsidiaries, engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States. The company offers Pemivibart, a half-life extended investigational monoclonal antibody for the pre-exposure prophylaxis prevention of COVID-19 in adults and adolescents through in… Read more